December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Early data suggest that the combination of itacitinib and calcineurin inhibitors as prophylaxis for GVHD was well tolerated in patients with hematologic malignancies undergoing stem cell transplantation.